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The mortality rate of patients who develop sepsis-related cardiac dysfunction is high.
Many disease conditions (e.g., diabetes) increase the susceptibility to infections and
subsequently sepsis. Activation of the NF-κB pathway plays a crucial role in the
pathophysiology of sepsis-associated cardiac dysfunction and diabetic cardiomyopathy.
The effect of diabetes on outcomes in patients with sepsis is still highly controversial.
We here hypothesized that type 2 diabetes (T2DM) augments the cardiac (organ)
dysfunction associated with sepsis, and that inhibition of the NF-κB pathway with
linagliptin attenuates the cardiac (organ) dysfunction in mice with T2DM/sepsis. To
investigate this, 10-week old male C57BL/6 mice were randomized to receive normal
chow or high fat diet (HFD), 60% of calories derived from fat). After 12 weeks, mice
were subjected to sham surgery or cecal ligation and puncture (CLP) for 24 h. At 1 hour
after surgery, mice were treated with linagliptin (10 mg/kg, i.v.), IKK-16 (1 mg/kg, i.v.),
or vehicle (2% DMSO, 3 ml/kg, i.v.). Mice also received analgesia, fluids and antibiotics
at 6 and 18 h after surgery. Mice that received HFD showed a significant increase in
body weight, impairment in glucose tolerance, reduction in ejection fraction (%EF), and
increase in alanine aminotransferase (ALT). Mice on HFD subjected to CLP showed
further reduction in %EF, increase in ALT, developed acute kidney dysfunction and lung
injury. They also showed significant increase in NF-κB pathway, iNOS expression, and
serum inflammatory cytokines compared to sham surgery group. Treatment of HFD-CLP
mice with linagliptin or IKK-16 resulted in significant reductions in (i) cardiac, liver, kidney,
and lung injury associated with CLP-sepsis, (ii) NF-κB activation and iNOS expression
in the heart, and (iii) serum inflammatory cytokine levels compared to HFD-CLP mice
treated with vehicle. Our data show that pre-existing type 2 diabetes phenotype worsens
the organ dysfunction/injury associated with CLP-sepsis in mice. Most notably, inhibition
of NF-κB reduces the organ dysfunction/injury associated with sepsis in mice with
pre-existing T2DM.
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INTRODUCTION
Sepsis is a dysregulated body response to infection that results
in life-threatening organ dysfunction (1). The cardiovascular
system is one of the important systems affected by sepsis. Most
septic patients, and all patients with septic shock, develop sepsis-
related cardiovascular dysfunction (2, 3), which is a key driver of
in-hospital mortality in these patients (4). Both the incidence of
sepsis and sepsis-related mortality increase with age due to the
presence of significant comorbidities including chronic kidney
disease and type 2 diabetes in the elderly (5). The prevalence of
diabetes is increasing worldwide (6). Patients with diabetes are at
high risk of developing diabetic cardiomyopathy, left ventricular
(LV) hypertrophy, ischemic cardiac injury, and heart failure (6–
9). Diabetic patients are more susceptible to both common and
rare infections and have a higher incidence of sepsis than patients
that do not suffer from the disease (10, 11). However, the effect of
diabetes on outcome in patients with infections is controversial
with some studies showing increased hospitalization, organ
dysfunction/injury, and mortality in diabetic patients with e.g.,
pneumonia (12–14), while other studies report either no effect
(15–17) or even protective effects (18–21). Hence, this study
was undertaken to investigate the effects of pre-existing type
2 diabetes mellitus (T2DM) caused by high fat diet (HFD) on
cardiac dysfunction in mice with sepsis.
Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are
among the most recently approved drugs for the treatment of
hyperglycemia in patients with T2DM. Gliptins mediate their
anti-diabetic effects by primarily inhibiting degradation of
endogenous glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP), resulting in
prolongation of postprandial insulin secretion. Given the
numerous and varied substrates enzymatically cleaved or bound
by DPP-4, DPP-4 inhibitors may have the potential to exhibit
a broader range of salutary pleiotropic effects in the heart
and vasculature, increasing the concentration of peptides with
potential vasoactive and cardioprotective effects, which may
be independent of GLP-1 and its receptor. DPP-4 signaling
cascade has been recently demonstrated to be involved also
in the pathologic features of sepsis, mainly due to a selective
cross-talk between DPP-4 and nuclear factor- kappa B (NF-κB)
signaling pathways (22–25). In sepsis, microbial components
activate different antigen presenting cells (APCs) after binding to
their Toll like receptor (TLR) 4 and 2. Exposed caveolin-1 from
the activated APC interacts with DDP-4 in T cells which results
in strong NF-κB activation in both the APCs and the T cells (23).
Adenosine deaminase (ADA) is another activator of DPP-4. The
activity of ADA in the serum is increased during inflammatory
diseases (e.g., sepsis) as a result of increased macrophages activity
(26) and the interaction of ADA with DPP-4 leads to NF-κB
activation in T cells (22). The expression of DPP-4 is increased in
diabetic patients (27–29).
Activation of NF-κB plays a crucial role in the
pathophysiology of both septic (30–32) and diabetic
cardiomyopathy (33). In sepsis, activation of NF-κB is secondary
to activation of TLR 2 and 4 by e.g., by wall fragments of Gram-
negative (e.g., lipopolysaccharide; LPS) or Gram-positive bacteria
(e.g., peptidoglycan; PepG) and/or pro-inflammatory cytokines
including tumor-necrosis factor-α (TNF-α) or interleukin-1
(IL-1). In addition to pro-inflammatory cytokines, the activation
of NF-κB in diabetes is also driven by free fatty acids (34)
(which activate TLR4) and advanced glycation end products
(which activate RAGE) (35). We have recently demonstrated that
inhibition of the activation of NF-κB by a selective IκB kinase
(IKK) inhibitor (IKK-16) attenuates the cardiac dysfunction
caused by sepsis in mice without co-morbidities (32) and in
mice with pre-existing chronic kidney disease (36). However,
the potential protective effects of the impairment of the cross-
talk between DDP-4 and NF-κB activation in sepsis-induced
multiorgan dysfunction have never been tested in animal models
of diet-induced diabetes, which is known to be characterized by
an increase in baseline NF-κB activity. Here we investigate (a)
the role of NF-κB activation in the cardiac dysfunction caused by
HFD with or without sepsis, (b) the effect of linagliptin treatment
on cardiac performance in the model of sepsis and T2DM. To
investigate the relative contribution of NF-κB inhibition in the
observed effects of linagliptin, IKK-16, a potent and selective




The animal protocols followed in this study were approved by the
local Animal Use and Care Committee in accordance with the
derivatives of both, the Home Office Guidance in the Operation
of Animals (Scientific Procedure Act 1986) published by Her
Majesty’s Stationary Office, the Guide for the Care and Use of
Laboratory Animals of the National Research Council (home
office project license, PPL: 70/8350) and by the local ethical
committee (DGSAF 0021573-P-12/11/2013) and are in keeping
with the European Directive 2010/63/EU as well as the 2011
Guide for the Care and Use of Laboratory Animals.
Animals
This study was conducted on 56 male C57BL/6 mice aged 10
weeks (Charles River, Kent, UK) weighing 25–30 g, receiving
a standard diet and water ad libitum (before starting the
experiments). Mice were housed 5 per cage in a temperature-
controlled room with a 12-h light/dark cycle.
High Fat Diet Model of Type 2 Diabetes
Mellitus
In this model of diet-induced obesity and insulin resistance, mice
(Charles River UK, Kent) were randomized to receive standard
chow diet [LabDiet R©, St. Louis (5053: protein provides 25%, fat
13%, and carbohydrate 62% of the total calories)] or high fat diet
[TestDiet R©, St. Louis (58Y1: Blue diet; protein provides 18.1%,
fat 61.6%, and carbohydrate 20.3% of the total calories)] with
free access to water for 12 weeks. Body weight, food intake, and
calories intake were measured weekly through the experiment to
monitor feeding behavior.
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Oral Glucose Tolerance Test (OGTT)
Mice were fasted for 6 h with free access to water. At the end of
the 6 h fasting, the body weight and fasting blood glucose were
measured using tail vein blood. Mice then received a bolus dose
of glucose (2 g/kg, dissolved in drinking water) via oral gavage.
Blood glucose levels were then measured at 15, 30, 45, 60, 90, and
120min post glucose administration using blood glucose meter
Accu-Chek R© (Accu-Chek Compact System; Roche Diagnostics,
Basel, Switzerland).
Insulin Tolerance Test (ITT)
Mice were fasted for 4 h with free access to water. At the end
of the 4 h fasting, the body weight and fasting blood glucose
were measured using tail vein blood. Mice then received a dose
of insulin aspart (NovoRapid R©) (0.75 U/kg, i.p.). Blood glucose
level was then measured at 15, 30, 45, 60, 90, and 120min
post insulin administration using blood glucose meter Accu-
Chek R© (Accu-Chek Compact System; Roche Diagnostics, Basel,
Switzerland).
Measuring Fasting Plasma Insulin
Mice were fasted for 6 h with free access to water. At the end
of the 6 h fasting period, blood samples were collected from
the tail vein. Fasting plasma insulin levels were then measured
using human insulin ELISA kit following the manufacturer’s
instructions (Abcam R©, Cambridge, UK).
Assessment of Baseline Kidney Function
During the last week of the experiment, mice were housed in the
metabolic cages to collect urine. They were housed (one mouse
per cage) for 24 h with free access to food and water. Urine
biochemistry (creatinine and sodium levels) was assessed blindly
by IDEXX the commercial veterinary testing laboratory (IDEXX
Ltd; West Sussex, UK). Urine albumin was measured using a
mouse albumin ELISA kit following manufacturer instructions
(Cambridge Bioscience R©, Cambridge, UK). Then creatinine
clearance (CrCl) and urine albumin to creatinine ratio (ACR)







Equation 1: Creatinine clearance (ml/min) is calculated using
four measurements (a) urine creatinine (µmol/L), (b) serum





Equation 2: Urine albumin to creatinine ratio is calculated using
2 (a) urine albumin (µg/L) and (b) urine creatinine (mg/L).
Assessment of Cardiac Function in vivo
(Echocardiography)
Echocardiography was conducted in vivo at baseline (before
sepsis challenge) then at 24 h after CLP to measure cardiac
function using a 30 MHz RMV707B scan head and a Vevo-770
imaging system (VisualSonics, Toronto, Ontario, Canada).
Animals were anesthetized using 3% isoflurane delivered with
0.4 l/min oxygen in the anesthesia chamber. After being sedated,
mice were then transferred to the echo table and taped from
the limbs in a supine position onto the metal ECG leads on
the Echo platform. Anesthesia was maintained during the whole
imaging process using 0.5–2% isoflurane delivered with 0.4 l/min
oxygen via nosecone under spontaneous breathing. The handling
platform was warmed to 40◦C in order to keep the core body
temperature of the mice. After being placed on the platform, the
fur on the chest was then removed carefully using Veet R© hair
removing cream. A pre-warmed echo gel is then applied to the
chest to start the measurement. At least 10min were left for the
animals to stabilize before any measurement was taken. The body
temperature was monitored using a rectal probe and the heart
rate was obtained from ECG tracing during the whole procedure.
Measurements from both two-dimensional (brightness mode,
B-mode) and one-dimensional (motion mode, M-mode) were
obtained. Measurements of the left ventricle internal dimension
(LVID) in both systole and diastole from the M-mode at the level
of the papillary muscles were used to calculate the percentage
ejection fraction (% EF), fractional shortening (% FS), and the
measurements of LV end-systolic and end-diastolic areas from
the B-mode were used to calculate the percentage functional area
change (% FAC) using the following equations:
% EF =
(LVID; d3 − LVID; s3)
LVID; d3
× 100
Equation 3: Ejection fraction (%) is calculated using 2
measurements (a) left ventricle internal dimension during
diastole (LVID;d, mm) and (b) left ventricle internal dimension
during systole (LVID;s, mm).
% FS =
(LVID; d− LVID; s)
LVID; d
× 100
Equation 4: Fractional shortening (%) is calculated using
2 measurements (a) left ventricle internal dimension during
diastole (LVID;d, mm) and (b) left ventricle internal dimension
during systole (LVID;s, mm).
% FAC =
(LVarea; d− LVarea; s)
LVarea; d
× 100
Equation 5: Fractional area change (%) is calculated using 2
measurements (a) left ventricle end-diastolic area (LV area;d,
mm2) and (b) left ventricle end-systolic area (LV area;s, mm2).
Model of Cecal Ligation and Puncture
(CLP) Induced Polymicrobial Sepsis
At 12 weeks after starting the HFD, mice fed either chow
or HFD were randomized to undergo either sham operation
or CLP surgery. Before surgery, mice were anesthetized using
(1.5 ml/kg, i.p.) of 2:1 ketamine (100 mg/ml): xylazine (20
mg/ml) solution. To obtain adequate analgesia, buprenorphine
(0.05 mg/kg, i.p.) was administered just before starting the
surgery. The fur of the abdomen was removed using Veet R©
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hair removing cream and the area cleaned with 70% ethanol.
A 1.5 cm midline incision of the abdomen was made and the
caecum was exposed. The caecum then was ligated below the
ileocecal valve and two punctures were made one at each end
using an 18-G needle. A small amount of fecal matter was then
squeezed from both punctures before the caecum was returned
to its anatomical position and the cut in the abdomen was then
sutured. Each mouse then received a resuscitation fluid (1ml
0.9% NaCl, s.c.). Mice were left on a homeothermic blanket
to recover then placed back into fresh clean cages. At 1 h
after CLP surgery, mice from the HFD group were randomized
to receive linagliptin (10 mg/kg, i.v), IKK-16 (1 mg/kg i.v.)
or vehicle (2% DMSO; 3 ml/kg, i.v.). At 6 and 18 h after
surgery, antibiotic (imipenem/cilastatin, 20 mg/kg) dissolved in
resuscitation fluid (15 ml/kg 0.9% NaCl, s.c.) was administered
along with analgesia (buprenorphine, 0.05 mg/kg, i.p.). At 24 h,
mice were anesthetized for assessment of cardiac function in vivo.
As a terminal procedure, mice were anesthetized using high
dose isoflurane (3% delivered in 0.9 l/min O2) before being
sacrificed. Blood samples were collected by cardiac puncture and
vital organs were collected and snap frozen using liquid nitrogen
then stored for further analysis at −80◦C freezer. Mice that
underwent sham surgery were anesthetized and handled in the
same manner as CLP mice during surgery. However, in animals
undergoing sham surgery, the cecum (although exposed) was not
subjected to perforation. At 1 h after surgery, sham mice were
treated with vehicle (2% DMSO, 3 ml/kg, i.v.) and they were also
treated with antibiotic (imipenem/cilastatin, 20 mg/kg) dissolved
in resuscitation fluid (15 ml/kg 0.9% NaCl, s.c.) along with
analgesia (buprenorphine, 0.05 mg/kg, i.p.) at 6 and 18 h after
surgery. Surgery, treatments and assessment of cardiac function
were performed by different member of the research team to
minimize subjective errors. The investigator assessing the cardiac
function was blinded as to the intervention that was used in the
study.
Western Blot Analysis
Immunoblot analyses of heart biopsies were carried out using a
semi-quantitative western blotting. We measured the degree of
phosphorylation of IKK, IκBα, and Akt, nuclear translocation
of p65 NF-κB subunit to the nucleus and inducible nitric oxide
synthase (iNOS) expression. For sample handling, blood was
withdrawn from mice at the time of euthanasia, heart tissue
was then washed with saline solution prior to homogenisation.
For sample preparation, a piece of heart tissue was taken and
diluted (1:10) with homogenisation buffer (HB) at 4◦C to obtain
a whole tissue lysate, that contains endothelium, cardiomyocytes
and leucocytes, for protein extraction. Cytosolic and nuclear
extracts from hearts were prepared as previously described (37).
Succinctly, hearts were homogenized at 10% (wt/vol) with a
Potter Elvehjem homogenizer (Wheaton, Millville, NJ) using
a homogenization buffer containing 20mM HEPES (pH 7.9),
1mM MgCl2, 0.5mM EDTA, 1% Nonidet P-40, 1mM EGTA,
1mM DTT, 0.5mM PMSF, 1 µl/ml of PIC. Homogenates were
centrifuged at 1,300 g for 5min at 4◦C. Supernatants were
removed and centrifuged at 16,000 g at 4◦C for 40min to
obtain supernatant containing the cytosolic fraction. The pelleted
nuclei were resuspended in extraction buffer (1/3 volume of
the homogenation buffer) containing 20mM HEPES (pH 7.9),
1.5mM MgCl2, 300mM NaCl, 0.2mM EDTA, 20% glycerol,
1mM EGTA, 1mM DTT, 0.5mM PMSF, 1 µl/ml of PIC,
and incubated in ice for 30min, followed by centrifugation at
16,000 g for 20min at 4◦C. The resulting supernatants containing
nuclear proteins were carefully removed. Both cytosolic and
nuclear proteins were measured using bicinchoninic acid (BCA)
protein assay following manufacturer’s directions (Therma
Fisher Scientific, Rockford, IL). Proteins were separated by gel
electrophoresis using sodium dodecyl sulfate polyacrylamide
(SDS-PAGE) then transferred into a Polyvinylidene difluoride
(PVDF) membrane. The membrane then was blocked 1 h
in 5% dry milk solution in TBS-tween). Incubation of the
membrane was conducted overnight at 4◦C with primary
antibody in 5% blocking solution then incubated the next day
with the appropriated HRP-conjugated secondary antibody at
room temperature for 30min and then detected with enhanced
chemilumescent (ECL) detection system and quantified by
densitometry using BioRad Image Lab SoftwareTM 6.0. Results
were normalized with respect to densitometric value of mouse
anti-tubulin for cytosolic and total proteins, and mouse anti-
histone H3 for nuclear proteins.
Cytokine Measurements
Serum cytokines levels (TNF-α, IL-6, KC, and IL-10) were
measured using a bead-based immunoassay method. Serum
samples were prepared and handled following manufacturer
instructions (Biolegend R©, San Diego, USA). Data was obtained
using a LSR Fortessa (Biociences R©, Berkshire, UK) and analyzed
using the LegendplexTM 7.1.0.0 software.
Measuring Myeloperoxidase (MPO) Activity
in the Lung
MPO was extracted from the tissues according to the methods
described by Barone et al. (38) with slight modifications to
measure neutrophil accumulation in the lungs. For samples
preparation, a piece of lung was diluted (1:20) with 5mM
potassium phosphate buffer to homogenize the sample (at
4◦C). For measurements of MPO activity, the homogenate
was centrifuged (at 13,000 RPM, 30min, 4◦C). The resulted
supernatant was discarded. A 5-time dilution with 0.5%
hexadecyl-trimethyl-ammonium bromide in 50mM potassium
phosphate buffer was used to suspend and homogenize the
pellet. The resulted solution was then frozen and thawed
three times followed by 10 s sonication at room temperature
and then incubated at 4◦C for 30min then centrifuged (at
12,500 RPM, 15min, 4◦C). MPO activity was measured in
the supernatant by mixing 100 µl of the supernatant with
0.167 mg/ml o-dianiside dihydrochloride and 0.0005% hydrogen
peroxide in 2.9ml 50mM potassium phosphate buffer. UV-
visible spectrophotometer was used to measure the change
in absorbance at 460 nm for 1.5min. MPO activity was
presented as the quantity of the enzyme degraded 1 µmol of
peroxide/min at 25◦C and expressed as µU/gram of the lung
tissue.
Frontiers in Immunology | www.frontiersin.org 4 December 2018 | Volume 9 | Article 2996
Al Zoubi et al. Diabetes, Sepsis, and Organ Dysfunction
Measuring N-acetyl-β-D-glucosaminidase
(NAG) Activity in the Lung
NAG activity was analyzed tomeasuremacrophage accumulation
in the lung. For samples preparation, a piece of lung was
diluted with 0.01M phosphate buffer saline and homogenized
(at 4◦C). The resulted solutions were then frozen and thawed
three times followed by 10 s sonication at room temperature
to break the cells. For measurements of NAG activity, the
homogenate was centrifuged (at 5,000 RPM, 30min, 4◦C). The
resulted supernatants were then used to measure NAG activity
using a NAGase ELISA kit following manufacturer instructions
(Elabscience R©, Houston, Texas, USA).
Statistical Analysis
Data was analyzed using GraphPad Prism 7.0 (GraphPad
Software, San Diego, California, USA). Values stated in the text
and figures are presented as a mean ± standard error of the
mean (SEM) of n observations, where n is the number of animals
used. Data was tested for normality using D’Agostino-Pearon
normality test and then assessed using One-way ANOVA test
followed by Bonferroni’s post-hoc test or unpaired Student t-test
where appropriate. P-values of less than 0.05 were considered to
be statically significant.
Materials
Unless otherwise stated, all materials, reagents, and solutions
were purchased from Sigma-Aldrich Ltd (Poole, Dorset, UK).
RESULTS
Diabetic Phenotype and Characterization
of Organ Dysfunction in Mice With
Experimental T2DM Caused by HFD
When compared to chow fed mice, mice fed a HFD showed
a significant increase in fasting blood glucose, impairment in
glucose tolerance after being challenged with an oral dose of
glucose, impairment in insulin tolerance after challenge with i.p.
insulin, an increase in fasting plasma insulin as well as an increase
in total cholesterol. Mice fed a HFD also showed significant
increases in (i) total body weight secondary to an increase in
fat mass, but not lean mass; (ii) an increase in the serum levels
of alanine aminotransferase (ALT) indicating the development
of liver injury; (iii) increase in urine albumin to creatinine
ratio (ACR) as well as a (iv) a decrease in creatinine clearance
(CrCl) indicating the development of diabetic nephropathy
(proteinuria) and glomerular dysfunction (P < 0.05). Mice
also showed mild cardiomyopathy as evidence by a small,
but significant, reduction in ejection fraction (EF%), fractional
shortening (FS%), and fractional area change (FAC%) (P < 0.05;
Table 1).
Pre-existing T2DM Augments the Multiple
Organ Dysfunction and Systemic
Inflammation Associated With Sepsis in
Mice
Subjecting mice on chow diet to CLP resulted in a small (but
not significant) effect on systolic cardiac function compared to
TABLE 1 | Baseline data for both chow and HFD groups before interventions
(CLP or sham surgeries).
Parameter Chow HFD
Net weight gain from baseline
(grams)
5.34 ± 0.47, n = 18 15.92 ± 1.19, n = 18*
Food intake$
(grams/mouse/week)
3.38 ± 0.02, n = 12
(weeks)




17.29 ± 0.12, n = 12
(weeks)
19.99 ± 0.24, n = 12
(weeks)*
AUC for OGTT (g.min/dl) 29.65 ± 0.55, n = 18 47.73 ± 2.96, n = 18*
AUC for ITT (g.min/dl) 6.57 ± 0.14, n = 5 9.63 ± 0.44, n = 10*
Fasting blood glucose (mg/dl) 183.9 ± 4.68, n = 18 294.9 ± 13.9, n = 18*
Fasting plasma insulin (µIU/ml) 20.16 ± 0.86, n = 10 71.80 ± 7.75, n = 9*
Ejection fraction (%) 71.92 ± 0.81, n = 18 64.26 ± 0.95, n = 18*
Fractional shortening (%) 40.73 ± 0.67, n = 18 34.73 ± 0.68, n = 18*
Fractional area change (%) 51.37 ± 0.41, n = 18 45.8 ± 1.14, n = 18*
Left ventricle mass (mg) 127.2 ± 2.92, n = 18 131.6 ± 4.04, n = 18
Urea (mmol/L) 9.47 ± 0.32, n = 18 9.45 ± 0.24, n = 18
Creatinine (µmol/L) 28.49 ± 1.71, n = 18 32 ± 1.25, n = 18
Alanine aminotransferase (U/L) 32.9 ± 4.05, n = 18 68.26 ± 9.54, n = 18*
Creatinine Clearance (ml/min) 154.1 ± 17.56, n = 14 96.55 ± 8.79, n = 18*
Urine Albumin to Creatinine Ratio
(µg/mg)
0.19 ± 0.02, n = 10 0.72 ± 0.07, n = 10*
Triglyceride (mg/dl) 183.6 ± 9.65, n = 18 175.4 ± 8.53, n = 18
Total cholesterol (mg/dl) 147.3 ± 2.24, n = 18 183.7 ± 3.56, n = 18*
Mice fed a HFD were compared to age-matched mice fed a chow diet. Data is presented
as mean ± SEM for n number of observations. Data was analyzed by unpaired t-test.
*P < 0.05 vs. the chow-fed group. $: mean food intake of 18 mice in each group during
the study period 12 weeks (n = 12). AUC, area under the curve; OGTT, oral glucose
tolerance test; ITT, insulin tolerance test
sham surgery (P > 0.05; Figure 1). However, mice fed a HFD
and subjected to CLP exhibited a large and significant reduction
in systolic cardiac function compared to sham surgery (P < 0.05;
Figure 1).
To understand the signaling mechanism associated with
cardiac dysfunction, we investigated the effect of HFD on the
activation of key signaling pathways of inflammation and cell
survival including pathways leading to the activation of NF-κB
with or without sepsis. Mice fed a HFD exhibited significant
increases in the phosphorylation of IKKα/β on Ser178/180,
the phosphorylation of IκBα on Ser32/36, the translocation of
p65 NF-κB to the nucleus, the expression of iNOS, and a
significant decrease in the phosphorylation of Akt on Ser473
(P < 0.05; Figures 2, 3). Exposing mice on chow diet to
CLP resulted in a similar degree of activation of NF-κB and,
indeed, iNOS expression (in the heart) as observed in mice
with HFD alone. CLP-sepsis in mice on HFD resulted in a
further increase in the phosphorylation of IKKα/β and IκBα, the
translocation of p65, and iNOS expression (P < 0.05; Figure 2)
with no significant effect on Akt phosphorylation (P > 0.05;
Figure 3).
We also studied the effect of HFD on the systematic synthesis
of key, NF-κB-dependent cytokines including TNF-α, IL-6, KC,
and IL-10. When compared to mice on chow diet, mice on HFD
for 12 weeks showed no significant changes in cytokines levels
(P > 0.05; Figure 2). When compared to mice on regular chow
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FIGURE 1 | Effects of CLP challenge and linagliptin or IKK-16 post treatment on cardiac function in mice with T2DM. Mice from chow and HFD groups were
randomized to undergo CLP or sham surgery. At 1 h after CLP, mice on HFD were randomized to receive linagliptin (10 mg/kg, i.v.), IKK-16 (1 mg/kg, i.v.), or vehicle
(2% DMSO, 3 ml/kg). Cardiac function was assessed at 24 h after CLP or sham surgery in mice fed a chow diet or a HFD. (A) Representative M-mode
echocardiograms; percentage % (B) EF, (C) FS, and (D) FAC. Data was analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as
mean ± SEM. *P < 0.05 compared to HFD+CLP group. (n = 8 for sham surgery groups and 10 for CLP groups).
diet subjected to sham surgery, mice on chow diet subjected
to CLP (in the presence of antibiotics) showed no significant
changes in cytokines levels in the serum (P > 0.05; Figure 4).
CLP-sepsis in mice on HFD resulted in large increases in the
serum levels of TNF-α, IL-6, KC, and IL-10 when compared to
mice on HFD subjected to sham surgery and mice on chow diet
subjected to CLP (P < 0.05; Figure 4).
Markers for lung inflammation were also measured to study
the effect of pre-existing diabetes on lung injury associated with
sepsis. When compared to micev on chow diet, mice on HFD
showed no significantv changes in MPO or NAG activities in the
lungs after sham surgery (P > 0.05; Figure 5). Whenv compared
to mice on regular chow diet subjected to sham surgery, mice on
chow diet subjected to CLP showed a significant increase in NAG
activity in the lung (P < 0.05; Figure 5) with no change in MPO
activity (P > 0.05; Figure 6). Subjecting mice on HFD to CLP
surgery resulted in big increases in bothMPO and NAG activities
when compared to mice on HFD subjected to sham surgery
and mice on chow diet subjected to the same CLP (P < 0.05;
Figure 5).
Our CLP-sepsis model with moderate severity had (in the
presence of antibiotics and fluid resuscitation) no effect on serum
creatinine, urea, or ALT compared to sham surgery (P > 0.05;
Figure 6). However, challenge of mice on HFDwith CLP resulted
(despite the presence of antibiotics and fluid resuscitation) in
significant increases in serum creatinine, urea, and ALT levels
(P < 0.05; Figure 6). These results indicate that pre-existing
T2DM increases the severity of both renal dysfunction and
hepatocellular injury.
Effect of Linagliptin Post Treatment on the
Multiple Organ Dysfunction Associated
With Sepsis in Mice With Pre-existing
T2DM
When compared to mice on HFD subjected to sham surgery,
mice on HFD subjected to CLP and treated with vehicle
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FIGURE 2 | Effects of CLP and linagliptin or IKK-16 post treatment on NF-κB signaling pathway in the heart of mice with pre-existing T2DM. Mice from chow and
HFD groups were randomized to undergo CLP or sham surgery. At 1 h after CLP, mice on HFD were randomized to receive linagliptin (10 mg/kg i.v.), IKK-16 (1 mg/kg
i.v.), or vehicle (2% DMSO, 3 ml/kg). At 24 h heart samples were collected and signaling events were assessed. Densitometry analysis of the bands is expressed as
relative optical density (O.D.) of (A) IKKα/β phosphorylation on Ser178/180 corrected to the corresponding total IKKα/β content and normalized using the related sham
band; (B) IκBα phosphorylation on Ser32/36 corrected to the corresponding total IκBα content and normalized using the related sham band; (C) NF-κB p65 subunit
levels in both, cytosolic and nuclear fractions expressed as a nucleus/cytosol ratio normalized using the related sham bands; (D) inducible nitric oxide synthase (iNOS)
expression corrected for the corresponding tubulin band and normalized using the related sham band. Data was analyzed using one-way ANOVA followed by
Bonferroni’s post-hoc test and expressed as mean ± SEM.*P < 0.05 compared to HFD+CLP group, $P < 0.05. (n = 4–6 per group).
developed significant systolic cardiac dysfunction. Treatment of
mice on HFD with linagliptin, at 1 h after CLP, attenuated the
systolic cardiac dysfunction caused by CLP (P < 0.05; Figure 1).
Having found that linagliptin attenuates the cardiac
dysfunction associated with CLP-sepsis in diabetic mice, we
then investigated the potential mechanism(s) of this beneficial
effect. Treatment of mice on HFD with linagliptin, at 1 h after
CLP, also resulted in significant reduction in IKKα/β and IκBα
phosphorylation, p65 translocation, and iNOS expression when
compared to mice on HFD subjected to CLP and treated with
vehicle (P < 0.05; Figure 2). Moreover, linagliptin treatment of
HFD/CLP mice restored the degree of Akt phosphorylation to
almost that seen in sham mice (P < 0.05; Figure 3).
Systemic inflammation was also attenuated after linagliptin
treatment. When compared to mice on HFD challenged CLP
and treated with vehicle, delayed treatment with linagliptin at 1 h
after CLP resulted in significant reduction in IL-6, KC, and IL-10
synthesis (P < 0.05; Figure 4) and in a reduction in TNF-α that
did not, however, reached statistical significance when compared
to mice treated with vehicle (P > 0.05, Figure 4).
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FIGURE 3 | Effects of CLP and linagliptin or IKK-16 post treatment on Akt
pro-survival pathway in the heart of mice with pre-existing T2DM. Mice from
chow and HFD groups were randomized to undergo CLP or sham surgery. At
1 h after CLP, mice on HFD were randomized to receive linagliptin (10 mg/kg
i.v.), IKK-16 (1 mg/kg i.v.), or vehicle (2% DMSO, 3 ml/kg). At 24 h, heart
samples were collected and signaling events were assessed. Densitometry
analysis of the bands is expressed as relative optical density (O.D.) of
phosphorylated Akt on Ser473 corrected for the corresponding total Akt
content and normalized using the related sham band. Data was analyzed
using one-way ANOVA followed by Bonferroni’s post hoc test and expressed
as mean ± SEM.*P < 0.05 compared to HFD+CLP group, $P < 0.05.
(n = 4–6 per group).
Accordingly, a significant reduction in markers of lung
inflammation, specifically the MPO and NAG activities, was
observed in the lungs of mice exposed to linagliptin post-
treatment when compared to mice on HFD subjected to CLP and
treated with vehicle only (P < 0.05, Figure 5).
When compared to mice on HFD subjected to CLP and
treated with vehicle, mice on HFD and treated with linagliptin, at
1 h after CLP, showed significant reduction in serum creatinine,
urea, and ALT levels indicating that linagliptin attenuated the
renal dysfunction and liver injury caused by CLP (P < 0.05;
Figure 6).
Effect of IKK-16 Post Treatment on the
Multiple Organ Dysfunction Associated
With Sepsis in Mice With Pre-existing
T2DM
In order to investigate whether inhibition of NF-κB was the main
reason of the attenuated organ injury caused by sepsis in diabetic
mice after linagliptin treatment, we have investigated the effects
of the specific IKK-inhibitor IKK-16 in these animals. When
compared to mice on HFD subjected to sham surgery, mice
on HFD subjected to CLP and treated with vehicle developed
significant systolic cardiac dysfunction. Delayed treatment of
HFD mice with IKK-16 at 1 h after CLP attenuated the
systolic cardiac dysfunction (P < 0.05; Figure 1) caused by
sepsis.
The restoration of cardiac function afforded by IKK-16 in
diabetic CLP-mice was accompanied by significant reduction
in IKKα/β and IκBα phosphorylation, p65 translocation, and
iNOS expression in mice treated with IKK-16 when compared
to mice on HFD challenged with CLP and treated with vehicle
(P < 0.05; Figure 2). Moreover, IKK-16 treatment restored the
Akt phosphorylation (P < 0.05; Figure 3) caused by HFDwith or
without sepsis.
When compared to mice on HFD subjected to CLP and
treated with vehicle, delayed treatment with IKK-16 at 1 h after
CLP resulted in significant reduction of both the systemic levels
TNF-α, IL-6, KC, and IL-10 (P < 0.05; Figure 4) and local (lung)
MPO and NAG activities (P < 0.05, Figure 5). They also showed
significant reduction of serum creatinine, urea, and ALT levels
indicating that IKK-16 reduced both the renal dysfunction and
the liver injury caused by sepsis inmice fed with a HFD (P< 0.05;
Figure 6).
Interestingly, no statistically significant differences between
the two post-treatment groups were recorded for any of the
measured markers.
DISCUSSION
Although the mortality rate among septic patients has declined
due to improved supportive care for patients in the ICU
(39), the incidence of sepsis has increased as a result of
the aging of the population (40) which is associated with
the presence of significant comorbidities such as T2DM (5).
Patients with T2DM are more likely to develop infections
and subsequently sepsis (10, 11). The cardiovascular system
is one of the most important systems affected by sepsis
and the development of cardiovascular dysfunction in sepsis
has been linked to several pathophysiological driver including
inflammatory cytokines and NO (32, 36). Many studies of
the pathophysiology of sepsis have shown beneficial effects in
pre-clinical models of sepsis. However, clinical studies that
tested the efficacy of drugs targeted at identical aspects of
the pathophysiology (often by using identical interventions)
have failed to improve survival in septic patients (as a result
of the limitations in both animal models and experimental
designs) (41).
In this study, a clinically relevant model of T2DM caused by
prolonged administration of HFD (for 12 weeks) was established
in C57BL/6 male mice. As the consumption of a western diet is
a key driver underlying the development of T2DM, our model
of feeding a HFD for longer periods recapitulates the main
cause of T2DM in humans and is considered to be one of
the most clinically, relevant model of T2DM to date. Indeed,
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FIGURE 4 | Effects of CLP challenge and linagliptin or IKK-16 post treatment on systemic inflammation in mice with T2DM. Mice from chow and HFD groups were
randomized to undergo CLP or sham surgery. At 1 h after CLP, mice on HFD were randomized to receive linagliptin (10 mg/kg, i.v.), IKK-16 (1 mg/kg, i.v.), or vehicle
(2% DMSO, 3 ml/kg). At 24 h after CLP, blood samples were collected and inflammatory cytokines concentrations were measured in the serum. (A) TNF-α, (B) IL-6,
(C) KC, and (D) IL-10. Data was analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as mean ± SEM. *P < 0.05 compared to
HFD+CLP group. (n = 4 per sham surgery group and n = 6–8 per CLP group).
feeding of mice with HFD resulted, within 12 weeks, in the
development of a diabetic phenotype (significant weight gain,
impaired glucose tolerance, increased fasting blood glucose and
increased fasting plasma insulin) and diabetic cardiomyopathy
(reduction in %EF) as a result of NF-κB activation in the heart
(see below).
A “two-hit” model of pre-existing T2DM (secondary to
HFD administration) followed by a mild CLP surgery (which
did not cause significant organ dysfunction in young and
healthy mice, but which we have reported to cause substantial
organ dysfunctions in old mice or mice with CKD) was
used to study (a) the effect of pre-existing T2DM on the
cardiac dysfunction associated with sepsis and (b) to test novel
therapeutic interventions aimed at reducing cardiac dysfunction
in T2DM/sepsis mice. We show here, for the first time, that
pre-existing T2DM augments the cardiac dysfunction associated
with sepsis. T2DM alone resulted in a small degree of NF-κB
activation and iNOS expression in the heart. However, sepsis
(second hit) in diabetic mice resulted in a dramatic increase in
the serum concentrations of proinflammatory cytokines and a
further increase in both NF-κB activation and iNOS expression
in the heart. Diabetes also resulted in reduction in the activation
(phosphorylation) of the Akt pro-survival pathway, while sepsis
resulted in further reduction of Akt phosphorylation in the
heart. These two findings suggest that the cardiac dysfunction
associated with T2DM/sepsis is most likely a result of the
activation of the NF-κB pro-inflammatory signaling pathway
(with subsequent increase in iNOS expression and serum
inflammatory cytokines levels) and the concomitant inhibition of
Akt pro-survival pathways.
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FIGURE 5 | Effects of CLP and linagliptin or IKK-16 post treatment on neutrophil/macrophage infiltration in the lung in mice with pre-existing T2DM. Mice from chow
and HFD groups were randomized to undergo CLP or sham surgery. At 1 h after CLP, mice on HFD were randomized to receive linagliptin (10 mg/kg, i.v.), IKK-16 (1
mg/kg, i.v.), or vehicle (2% DMSO, 3 ml/kg). At 24 h after CLP, lung samples were collected and neutrophil and macrophages infiltration were measured as the
(A) MPO and (B) NAG activities. Data was analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as mean ± SEM for n number of
observations. *P < 0.05 compared HFD+CLP group. $P < 0.05 (n = 6 per group).
FIGURE 6 | Effects of CLP and linagliptin or IKK-16 post treatment on renal dysfenction and hepatocelleular injury in mice with pre-existing T2DM. Mice from chow
and HFD groups were randomized to undergo CLP or sham surgery. At 1 h after CLP, mice on HFD were randomized to receive linagliptin (10 mg/kg, i.v.), IKK-16 (1
mg/kg, i.v.), or vehicle (2% DMSO, 3 ml/kg). At 24 h after CLP, blood samples were collected and serum (A) urea, (B) creatinine, and (C) ALT levels were measured.
Data was analyzed using one-way ANOVA followed by Bonferroni’s post-hoc test and expressed as mean ± SEM. *P < 0.05 compared to HFD+CLP group. (n = 8
per sham surgery group, n = 10 per CLP groups).
The DPP-4 inhibitors gliptins (e.g., linagliptin and sitagliptin)
have been used as anti-diabetic drugs that exert their catalytic
effect by increasing the incretin levels. However, recent evidence
indicates that DPP-4 inhibitors, as well as glucagon like peptide-
1 (GLP-1) receptors agonists (e.g., liraglutide), also have anti-
inflammatory effects. The (off-target) non-catalytic effects of
DPP-4 inhibitors have recently been discussed in the literature
as a potential new therapeutic strategy for the treatment
of diseases associated with local or systemic inflammation.
Indeed, some preclinical studies suggest that inhibition of DPP-
4 by different gliptins results in less cardiac dysfunction in
a murine model of HFD-induced fibrosis and inflammation
(42) and in a rat model of heart failure (43) by inhibiting
NF-κB and by reducing the formation of pro-inflammatory
cytokines. The effect of some gliptins and GLP-1 receptor
agonists on survival and inflammation was also studied in animal
models of endotoxaemia. Rodents subjected to endotoxaemia
and treated with linagliptin or liraglutide (or their respective
vehicles) showed an increase in survival rate (44, 45), and
decreased formation of reactive oxygen species (ROS) (46).
Treatment of cardiomyocytes with sitagliptin decreased the
inflammatory response triggered by LPS (47). In contrast,
pre-treatment with sitagliptin had no effect on survival in
endotoxaemic animals (44, 45). Furthermore, treatment of
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endotoxaemic mice with vildagliptin ameliorated the degree
of pulmonary fibrosis (48). However, the effect of DPP-4
inhibitors on the cardiac (organ) dysfunction associated with
sepsis (in the absence or presence of diabetes) has not yet been
investigated.
Based on previous work in animals with sepsis (without
T2DM), we have hypothesized that the activation of NF-κB (pro-
inflammatory) and the inhibition of Akt (pro-survival) pathways
are the reasons for the cardiac dysfunction in T2DM/sepsis
and, hence, studied the effect of linagliptin (repurposing of
linagliptin) on NF-κB inhibition and Akt activation and their
impact on cardiac performance. Indeed, the results of this
study highlighted, for the first time, that inhibition of DPP-
4 using linagliptin (at 1 h after CLP) attenuates the cardiac
dysfunction associated with T2DM/CLP-sepsis and this was
associated with, or occurred as a result of, an inhibition of NF-
κB activation and preservation of Akt pathway activation in the
heart. Treatment with linagliptin also resulted in attenuation
of the multiple organ dysfunction associated with T2DM/CLP-
sepsis.
To confirm the potential key role of the activation of NF-κB
in the pathophysiology of septic cardiomyopathy in animals with
T2DM, we investigated the effect of NF-κB pathway inhibition
using a selective IKK inhibitor (IKK-16) on cardiac (organ)
dysfunction associated with sepsis. Treatment with IKK-16
ameliorated the cardiac dysfunction in mice with T2DM/sepsis.
This enhanced cardiac function was a result of the decreased
NF-κB activation (and iNOS expression) and inflammatory
cytokines synthesis and the restored Akt phosphorylation. This
restoration of Akt phosphorylation can be a result of heat
shock protein 90 (Hsp 90) binding to the α and β subunits
of IKK as well as to endothelial nitric oxide synthase (eNOS)
(49, 50). The interaction of Hsp90 and eNOS creates a complex
with Akt which allows eNOS and Akt to function on the
same domain of Hsp90 (51). This interaction is increased when
IKK is inhibited, resulting in increased Akt-eNOS pathway
activation (52). Many other studies showed that pharmacological
interventions that inhibit NF-κB reduced the multiple organ
dysfunction associated with sepsis (32, 36, 53). Indeed, in this
study a single dose of IKK-16 at 1 h after CLP resulted in
attenuation of the multiple organ dysfunction associated with
T2DM/sepsis.
Although we cannot exclude that other effects associated with
DPP-4 inhibition (that do not involve NF-κB inhibition) may
have contributed to the observed beneficial effects of linagliptin,
our data demonstrating that the magnitude of the effect of the
inhibition of NF-κB with IKK-16 is similar to the one observed
with linagliptin supports the view that inhibition of the activation
of NF-κB is at the heart of the observed beneficial effects of
both linagliptin and IKK-16. Our data also indicate (and indeed
support the view of other publications) that linagliptin may be
“repurposed” for the use in sepsis and/or other conditions that
are associated with local or systemic inflammation driven by the
excessive activation of NF-κB.
CONCLUSIONS AND LIMITATIONS
Our data shows that a pre-existing, diabetic phenotype worsens
the cardiac (organ) dysfunction associated with CLP-sepsis in
mice. It also shows that activation of the NF-κB pathway is a
key driver of cardiac dysfunction in mice with T2DM/sepsis.
Most notably, it shows, for the first time, that inhibition of NF-
κB using linagliptin or IKK-16 attenuates this cardiac (organ)
dysfunction even in mice with pre-existing T2DM. Therefore,
targeting NF-κB activation may be a potential strategy to treat
the excessive inflammation and cardiac (organ) dysfunction
in patients with T2DM and sepsis. However, our study was
conducted in relatively young mice (22-week old) and treatment
of septic mice was introduced relatively early in the disease
course (at 1 h of the induction of sepsis) in mice treated with
antibiotics and fluids to mimic “standard care” in humans
with sepsis. Clearly, more studies are needed to elucidate
how late after the onset of sepsis linagliptin or IKK-16 can
be administered to attenuate the cardiac (organ) dysfunction,
especially in older mice (ideally 12 to 18-month old). The
latter studies are often limited by either the availability of
mice of a relevant age or cost of these animals (and often
both). This is of particular importance as most cases of
sepsis occur in elderly and they are usually diagnosed later
in the disease when patients either have already developed
multiple organ dysfunctions or, at least, significant cardiovascular
abnormalities. Further studies using other DPP-4 inhibitors
and/or GLP-1 receptor agonists are needed to investigate
whether any of the observed beneficial effects of linagliptin
are secondary to the increased incretin levels or are, indeed, a
direct effect of DPP-4 inhibition and to determine whether the
inhibition of NF-κB reported with linagliptin in our study is,
indeed, a unique class-specific effect or an off-target effect of
linagliptin.
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